scholarly journals A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris.

Circulation ◽  
1987 ◽  
Vol 75 (6) ◽  
pp. 1192-1199 ◽  
Author(s):  
H K Gold ◽  
J A Johns ◽  
R C Leinbach ◽  
T Yasuda ◽  
E Grossbard ◽  
...  
Keyword(s):  
Angina Pectoris ◽  
Unstable Angina ◽  
Plasminogen Activator ◽  
Human Tissue ◽  
Controlled Trial ◽  
Unstable Angina Pectoris ◽  
Tissue Type ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator

Recombinant tissue-type plasminogen activator followed by heparin compared with heparin alone for refractory unstable angina pectoris

1990 ◽  
Vol 66 (12) ◽  
pp. 910-914 ◽  
Author(s):  
Diego Ardissino ◽  
Paolo Barberis ◽  
Stefano De Servi ◽  
Antonio Mussini ◽  
Alberto Rolla ◽  
...  
Keyword(s):  
Angina Pectoris ◽  
Unstable Angina ◽  
Plasminogen Activator ◽  
Unstable Angina Pectoris ◽  
Tissue Type ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator

scholarly journals Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.

Circulation ◽  
1984 ◽  
Vol 70 (6) ◽  
pp. 1012-1017 ◽  
Author(s):  
D Collen ◽  
E J Topol ◽  
A J Tiefenbrunn ◽  
H K Gold ◽  
M L Weisfeldt ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Human Tissue ◽  
Controlled Trial ◽  
Tissue Type ◽  
Tissue Type Plasminogen Activator ◽  
Coronary Thrombolysis ◽  
Type Plasminogen Activator

scholarly journals Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator in rabbits

Blood ◽  
1986 ◽  
Vol 67 (5) ◽  
pp. 1493-1497 ◽  
Author(s):  
H Bounameaux ◽  
JM Stassen ◽  
C Seghers ◽  
D Collen
Keyword(s):  
Blood Flow ◽  
Plasminogen Activator ◽  
Human Tissue ◽  
Femoral Vein ◽  
Liver Blood Flow ◽  
Tissue Type ◽  
Tissue Type Plasminogen Activator ◽  
Cardiovascular Failure ◽  
Type Plasminogen Activator ◽  
Impaired Liver

Abstract The influence of the presence of fibrin microclots on the systemic fibrinogenolytic effects of intravenous (IV) recombinant human tissue- type plasminogen activator (rt-PA) was studied by injection of a homogenized fibrin suspension in the femoral vein or artery in rabbits. A linear correlation (P less than .001) was found between the extent of fibrinogen breakdown and the amount of fibrin (0 to 32 mg/kg) injected just prior to the IV infusion of rt-PA at a rate of 10 micrograms/kg/min for 60 minutes. This finding suggests that the systemic activation of the fibrinolytic system observed in some patients during infusion of rt-PA may be due, at least in part, to the presence of fibrin in the vascular bed. The effect of blood flow in the liver on the turnover of rt-PA was measured in rabbits after ligation of the hepatic artery and monitoring of the blood flow in the portal vein with a peristaltic pump. The half-life (t1/2) of rt-PA in plasma was inversely correlated with the logarithm of the rate of the liver blood flow. A doubling of the plasma t1/2 of rt-PA was observed after an eightfold reduction of the liver blood flow, suggesting that delayed clearance of rt-PA may occur in patients with severe cardiovascular failure and impaired liver blood flow.

Sign in / Sign up

Export Citation Format

Share Document